UK markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
143.31-0.40 (-0.28%)
At close: 04:00PM EDT
146.71 +3.40 (+2.37%)
After hours: 07:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 18.12B
Enterprise value 16.99B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.79
Price/book (mrq)N/A
Enterprise value/revenue 9.29
Enterprise value/EBITDA -78.92

Trading information

Stock price history

Beta (5Y monthly) 0.40
52-week change 3-29.01%
S&P500 52-week change 322.36%
52-week high 3218.88
52-week low 3141.98
50-day moving average 3150.17
200-day moving average 3172.76

Share statistics

Avg vol (3-month) 3842.66k
Avg vol (10-day) 3486.16k
Shares outstanding 5126.45M
Implied shares outstanding 6126.45M
Float 8125.41M
% held by insiders 10.41%
% held by institutions 195.02%
Shares short (15 Apr 2024) 42.5M
Short ratio (15 Apr 2024) 44.49
Short % of float (15 Apr 2024) 42.28%
Short % of shares outstanding (15 Apr 2024) 41.98%
Shares short (prior month 15 Mar 2024) 42.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -24.08%
Operating margin (ttm)-26.47%

Management effectiveness

Return on assets (ttm)-4.78%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)1.83B
Revenue per share (ttm)14.64
Quarterly revenue growth (yoy)31.20%
Gross profit (ttm)N/A
EBITDA -228.12M
Net income avi to common (ttm)-440.24M
Diluted EPS (ttm)-3.53
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.44B
Total cash per share (mrq)19.37
Total debt (mrq)2.68B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.08
Book value per share (mrq)-1.75

Cash flow statement

Operating cash flow (ttm)104.16M
Levered free cash flow (ttm)146.53M